Please login to the form below

Not currently logged in
Email:
Password:

BMS hires Roche's Mike Burgess to lead drug discovery

Was previously interim head of research and early development at Swiss pharma company

Mike Burgess, BMSMike Burgess has left Roche to become senior VP, discovery medicine and clinical pharmacology at Bristol-Myers Squibb.

Most recently, he was interim head of research and early development at Roche - a position now occupied by John Reed - and had previously led the Swiss pharma firm's oncology discovery and translational area at the same time as serving as head of global large molecule research.

In his new role, he will report to Dr Francis Cuss, senior VP research, R&D, and will be a member of BMS's research senior leadership team.

“As a physician scientist with a PhD in molecular biology, clinical experience in paediatrics and paediatric oncology, and extensive pharmaceutical industry and leadership experience, I believe Mike will be an important addition to our research and development organisation,” said Dr Cuss.

“Mike's broad clinical expertise, cross-therapeutic global team leadership and proven operational excellence will enable Bristol-Myers Squibb to continue to execute its strategy of ensuring sustainable delivery of an innovative pipeline of new medicines for patients.”

Prior to joining Roche, Dr Burgess was a medical fellow at Lilly, having completed his PhD at the University of Bristol in the UK.

21st January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics